Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Debt: 2020-2024

Historic Non-Current Debt for Oncology Institute (TOI) over the last 4 years, with FY2024 value amounting to $93.1 million.

  • Oncology Institute's Non-Current Debt fell 1676.04% to $76.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year decrease of 1676.04%. This contributed to the annual value of $93.1 million for FY2024, which is 726.16% up from last year.
  • As of FY2024, Oncology Institute's Non-Current Debt stood at $93.1 million, which was up 726.16% from $86.8 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Non-Current Debt registered a high of $93.1 million during FY2024, and its lowest value of $6.6 million during FY2020.
  • Over the past 4 years, Oncology Institute's median Non-Current Debt value was $83.7 million (recorded in 2022), while the average stood at $66.8 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 769.65% in 2023, then surged by 726.16% in 2024.
  • Oncology Institute's Non-Current Debt (Annual) stood at $6.6 million in 2020, then surged by 1128.79% to $80.6 million in 2022, then grew by 7.7% to $86.8 million in 2023, then rose by 7.26% to $93.1 million in 2024.
  • Its Non-Current Debt was $93.1 million in FY2024, compared to $86.8 million in FY2023 and $80.6 million in FY2022.